Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2006-7-6
pubmed:abstractText
Standardized allergen vaccines have been developed and registered as biopharmaceutical products in Cuba. Three different vaccines were obtained from the most relevant allergenic mite species: Dermatophagoides pteronvssinus, Dermatophagoides siboney, and Blomia tropicalis. Immuno-analytical methods based on murine monoclonal antibodies and human IgE antibodies were developed for assessing allergenic potency, composition, and stability. Preclinical and clinical studies showed efficacy and safety in diagnostic prick-tests and subcutaneous immunotherapy in asthmatic patients. New approaches are now undertaken in order to develop new adjuvanted formulations based on liposomes or proteoliposomes from Neisseria meningitidis, and purified allergens; aiming to overcome the drawbacks of conventional immunotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
12
pubmed:volume
24 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S2-36-7
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
State of the art in developing allergen vaccines in Cuba: prospects of novel adjuvanted vaccines.
pubmed:affiliation
Allergens Department, Centro Nacional de Biopreparados, P.O. Bor 6048, Havana 10600, Cuba. labrada@biocen.cu
pubmed:publicationType
Journal Article